See more : Kayne Anderson BDC, Inc. (KBDC) Income Statement Analysis – Financial Results
Complete financial analysis of Epitomee Medical Ltd (EPIT.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Epitomee Medical Ltd, a leading company in the Medical – Devices industry within the Healthcare sector.
- Nath Bio-Genes (India) Limited (NATHBIOGEN.NS) Income Statement Analysis – Financial Results
- Fraser and Neave, Limited (FNEVY) Income Statement Analysis – Financial Results
- Vuzix Corporation (VUZI) Income Statement Analysis – Financial Results
- Shanghai Shen Lian Biomedical Corporation (688098.SS) Income Statement Analysis – Financial Results
- CEIBA Investments Limited (CBA.L) Income Statement Analysis – Financial Results
Epitomee Medical Ltd (EPIT.TA)
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 10.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.80M | 7.79M | 6.18M | 3.10M | 2.47M |
| General & Administrative | 717.00K | 778.00K | 586.00K | 254.00K | 196.00K |
| Selling & Marketing | 60.00K | 18.00K | 170.00K | 0.00 | 0.00 |
| SG&A | 777.00K | 796.00K | 756.00K | 254.00K | 196.00K |
| Other Expenses | 9.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.76M | 11.07M | 8.77M | 3.85M | 3.27M |
| Cost & Expenses | 16.76M | 11.07M | 8.77M | 3.85M | 3.27M |
| Interest Income | 1.60M | 591.00K | 65.00K | 87.00K | 68.00K |
| Interest Expense | 57.00K | 11.00K | 2.71M | 66.00K | 82.00K |
| Depreciation & Amortization | 639.00K | 356.00K | 235.00K | 231.00K | 194.00K |
| EBITDA | -4.99M | -15.02M | -8.57M | -2.87M | -3.21M |
| EBITDA Ratio | -49.86% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.76M | -11.07M | -8.77M | -3.85M | -3.27M |
| Operating Income Ratio | -67.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.08M | -4.32M | -2.74M | 681.00K | -215.00K |
| Income Before Tax | -5.68M | -15.39M | -11.52M | -3.17M | -3.49M |
| Income Before Tax Ratio | -56.82% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.31M | -34.00K | 747.00K | -133.00K |
| Net Income | -5.68M | -15.39M | -11.52M | -3.17M | -3.49M |
| Net Income Ratio | -56.82% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.19 | -0.52 | -6.55 | -0.11 | -0.12 |
| EPS Diluted | -0.19 | -0.52 | -6.55 | -0.11 | -0.12 |
| Weighted Avg Shares Out | 29.60M | 29.46M | 1.76M | 29.46M | 29.46M |
| Weighted Avg Shares Out (Dil) | 29.60M | 29.46M | 1.76M | 29.46M | 29.46M |
Source: https://incomestatements.info
Category: Stock Reports